EP1545572A4 - Durch zelloberflächenproteasen aktivierte konjugate und therapeutische verwendungen davon - Google Patents

Durch zelloberflächenproteasen aktivierte konjugate und therapeutische verwendungen davon

Info

Publication number
EP1545572A4
EP1545572A4 EP02739474A EP02739474A EP1545572A4 EP 1545572 A4 EP1545572 A4 EP 1545572A4 EP 02739474 A EP02739474 A EP 02739474A EP 02739474 A EP02739474 A EP 02739474A EP 1545572 A4 EP1545572 A4 EP 1545572A4
Authority
EP
European Patent Office
Prior art keywords
cell surface
therapeutic uses
surface proteases
conjugates
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739474A
Other languages
English (en)
French (fr)
Other versions
EP1545572A2 (de
Inventor
Edwin L Madison
Joseph Edward Semple
George P Vlasuk
Scott Jeffrey Kemp
Mallareddy Komandla
Daniel Vanna Siev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Corp
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Publication of EP1545572A2 publication Critical patent/EP1545572A2/de
Publication of EP1545572A4 publication Critical patent/EP1545572A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
EP02739474A 2001-05-23 2002-05-23 Durch zelloberflächenproteasen aktivierte konjugate und therapeutische verwendungen davon Withdrawn EP1545572A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29326701P 2001-05-23 2001-05-23
US293267P 2001-05-23
PCT/US2002/016819 WO2002095007A2 (en) 2001-05-23 2002-05-23 Conjugates activated by cell surface proteases and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
EP1545572A2 EP1545572A2 (de) 2005-06-29
EP1545572A4 true EP1545572A4 (de) 2006-04-12

Family

ID=23128397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739474A Withdrawn EP1545572A4 (de) 2001-05-23 2002-05-23 Durch zelloberflächenproteasen aktivierte konjugate und therapeutische verwendungen davon

Country Status (5)

Country Link
EP (1) EP1545572A4 (de)
JP (1) JP2005518332A (de)
KR (1) KR20040004642A (de)
CA (1) CA2447023A1 (de)
WO (1) WO2002095007A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1230349B1 (de) 1999-11-18 2007-06-13 Dendreon Corporation Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
EP1383884A4 (de) 2001-03-22 2004-12-15 Dendreon Corp Serinprotease cvsp14 codierende nukleinsäuremoleküle, die codierten polypeptide sowie darauf beruhende verfahren
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
WO2004011654A1 (ja) * 2002-07-31 2004-02-05 Yamanouchi Pharmaceutical Co., Ltd. 新規セリンプロテアーゼ
CA2535265C (en) 2003-08-22 2014-01-28 Dendreon Corporation Compositions and methods for the treatment of disease associated with trp-p8 expression
CA2590751A1 (en) 2004-12-13 2006-06-22 Roy Rabindranauth Sooknanan Polynucleotides and polypeptide sequences involved in the process of bone remodeling
MX2008004693A (es) 2005-10-21 2008-09-03 Catalyst Biosciences Inc Proteasas modificadas que inhiben la activacion del complemento.
SI1986622T1 (sl) 2006-02-15 2014-02-28 Dendreon Corporation Malomolekulski modulatorji aktivnosti Trp-p8
US7772266B2 (en) 2006-02-15 2010-08-10 Dendreon Corporation Small-molecule modulators of TRP-P8 activity
KR100906145B1 (ko) * 2006-05-30 2009-07-03 한국생명공학연구원 Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제
NZ596269A (en) 2006-07-05 2012-12-21 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2353609A1 (de) 2010-02-04 2011-08-10 Sanofi Pasteur Immunisierungszusammensetzungen und -verfahren
US9869021B2 (en) 2010-05-25 2018-01-16 Aventa Technologies, Inc. Showerhead apparatus for a linear batch chemical vapor deposition system
CN103069555B (zh) 2010-08-18 2016-10-26 独立行政法人产业技术综合研究所 有机半导体薄膜以及有机半导体单晶薄膜的制造方法
EP2814807A4 (de) * 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc Lineare peptidantibiotika
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CA2878599A1 (en) 2012-07-24 2014-01-30 Jiansheng Yao Vaccine compositions for prevention against dengue virus infection
SG11201500579SA (en) 2012-07-25 2015-02-27 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
HRP20191860T1 (hr) 2013-03-13 2019-12-27 Forma Therapeutics, Inc. Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
AU2018290281B2 (en) 2017-06-22 2021-12-16 Vertex Pharmaceuticals Incorporated Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP3932935A1 (de) * 2020-06-29 2022-01-05 Centre National de la Recherche Scientifique Antibakterielle peptide
KR102938819B1 (ko) * 2022-08-22 2026-03-17 주식회사 서지넥스 막관통(transmembrane) 펩타이드(peptide)를 포함하는 표적세포 약물전달용 지질나노구조물 복합체 및 이의 용도
WO2024150172A1 (en) * 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Cleavable peptides and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036604A2 (en) * 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
WO2001068145A2 (en) * 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
WO2003000201A2 (en) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
WO2003068934A2 (en) * 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
WO2003104394A2 (en) * 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
EP1161266A4 (de) * 1999-03-12 2007-09-19 Univ Georgetown Matriptase, ein serinprotease, und dessen verwendungen
US20030180804A1 (en) * 2001-10-29 2003-09-25 Corvas International, Inc Solid phase synthesis of chemical libraries

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036604A2 (en) * 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
WO2001068145A2 (en) * 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
WO2003000201A2 (en) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
WO2003068934A2 (en) * 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
WO2003104394A2 (en) * 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARSKY V M ET AL: "The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.", JOURNAL OF MEDICINAL CHEMISTRY. 22 NOV 2001, vol. 44, no. 24, 22 November 2001 (2001-11-22), pages 4216 - 4224, XP002355780, ISSN: 0022-2623 *
MASQUELIER M ET AL: "AMINO ACID AND DIPEPTIDE DERIVATIVES OF DAUNORUBICIN. 1. SYNTHESIS,PHYSICOCHEMICAL PROPERTIES, AND LYSOSOMAL DIGESTION", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 23, no. 11, 1980, pages 1166 - 1170, XP000914522, ISSN: 0022-2623 *
TAKEUCHI T ET AL: "Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 25 AUG 2000, vol. 275, no. 34, 25 August 2000 (2000-08-25), pages 26333 - 26342, XP002355779, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP1545572A2 (de) 2005-06-29
CA2447023A1 (en) 2002-11-28
WO2002095007A2 (en) 2002-11-28
KR20040004642A (ko) 2004-01-13
JP2005518332A (ja) 2005-06-23
WO2002095007A3 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
EP1463742A4 (de) Neue pyrazolo- und pyrrolo-pyrimidine und ihre verwendungszwecke
GB0016787D0 (en) Compounds useful in therapy
EP1539941A4 (de) Adzyme und deren verwendungen
GB0028429D0 (en) Therapy
AU9153601A (en) Portable sauna
EP1408978A4 (de) Neue phenylamino-pyrimidine und ihre verwendungszwecke
IL154553A0 (en) Urocortin-iii and uses thereof
GB0124730D0 (en) Improvements in or relating to devices
AU2001236562A1 (en) Portable spa
EP1513866A4 (de) Assaykonjugat und dessen verwendung
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2003274402A1 (en) Fabric column and pad concrete form
EP1408985A4 (de) Neue pyridopyrimidone und ihre verwendungszwecke
AU2003231827A8 (en) Pseudo-tissues and uses thereof
GB0115780D0 (en) Therapeutic molecules and uses thereof
GB0102717D0 (en) Cells and uses therefor
EP1585971A4 (de) a-AMYLASE-ASSAY UND VERWENDUNGEN DAVON
AUPQ884500A0 (en) Novel therapeutic molecules and uses therefor - III
GB0014046D0 (en) Compounds useful in therapy
AU2003216442A8 (en) Enkurin and uses thereof
GB0128167D0 (en) Improvements in keyboards
AU2002304728A1 (en) Enzymes combination coadjuvating in the interferon therapy
AU2001272919A1 (en) Lp120 polypeptides and therapeutic uses thereof
AU2002952657A0 (en) Therapeutic agents and uses therefor-II
AUPR073300A0 (en) Novel therapeutic molecules and uses therefor - V

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060915